SCHEMBL7600283

SCHEMBL7600283

CCCCC(CCCC)NC(=O)N(C=O)CCCCNC(=O)C1COc2ccccc2O1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.63
POLB P06746 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
GAA P10253 3/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
TSHR P16473 1/20 0.47
ALOX5 P09917 1/20 0.46
ALDH1A1 P00352 4/20 0.45
KDM4E B2RXH2 2/20 0.45
HTT P42858 1/20 0.44
RAB9A P51151 2/20 0.44
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
GLA P06280 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8265142 0.71 HPGD (0.73) HPGDPOLBMEN1KMT2AGAA
SCHEMBL11013240 0.70 HPGD (0.75) HPGDPOLBMEN1KMT2AGAA
SCHEMBL7339035 0.70 HPGD (0.71) HPGDPOLBMEN1KMT2AGAA
SCHEMBL14923269 0.69 HPGD (0.68) HPGDPOLBMEN1KMT2AGAA
SCHEMBL7603785 0.68 NPY5R (0.44) HPGDMEN1KMT2ACYP3A4CYP2D6
SCHEMBL708029 0.68 POLB (0.77) HPGDPOLBMEN1KMT2AGAA
SCHEMBL5007799 0.68 HPGD (0.64) HPGDPOLBMEN1KMT2AGAA
SCHEMBL12499902 0.67 TAS1R3 (0.61) HPGDKMT2ATSHRALDH1A1HTT
SCHEMBL4651767 0.67 RAB9A (0.71) HPGDPOLBMEN1KMT2AGAA
SCHEMBL7603836 0.66 NAAA (0.44) POLBCYP3A4CYP2D6CYP2C19LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183252-B2 Heterocyclic aspartyl protease inhibitors SCHERING CORPORATION (US) 2012-05-22 US disclosed
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS SCHERING CORPORATION 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100292203-A1 HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS CHRM1, CHRM2, PRSS1 HPGD 2404/4885POLB 2893/4885MEN1 1192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.